Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2018 Mar 22. pii: haematol.2017.183475. doi: 10.3324/haematol.2017.183475. [Epub ahead of print] No abstract available.

2.

Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.

Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Björkholm M, Kristinsson SY, Hultcrantz M.

Leukemia. 2018 Jan 30. doi: 10.1038/s41375-018-0027-y. [Epub ahead of print]

PMID:
29535425
3.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

4.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.

PMID:
29335713
5.

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Thorsteinsdottir S, Lund SH, Lindqvist EK, Thordardottir M, Sigurdsson G, Costello R, Burton D, Steingrimsdottir H, Gudnason V, Eiriksdottir G, Siggeirsdottir K, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Dec 21;1(27):2790-2798. doi: 10.1182/bloodadvances.2017010454. eCollection 2017 Dec 26.

6.

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, Jethava YS, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.

7.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

8.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

9.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist UH, Blimark C, Turesson I.

Eur J Haematol. 2017 Sep;99(3):216-222. doi: 10.1111/ejh.12907. Epub 2017 Jun 28.

PMID:
28544116
10.

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Björkholm M, Kristinsson SY.

Ann Hematol. 2017 Feb;96(2):261-269. doi: 10.1007/s00277-016-2859-8. Epub 2016 Nov 2.

11.

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.

Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.

12.

Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.

Kjellander C, Björkholm M, Källman O, Giske CG, Weibull CE, Löve TJ, Landgren O, Kristinsson SY.

Ann Hematol. 2016 May;95(6):871-9. doi: 10.1007/s00277-016-2643-9. Epub 2016 Mar 15.

PMID:
26976017
13.

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends.

Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J.

BMJ Open. 2016 Jan 21;6(1):e009584. doi: 10.1136/bmjopen-2015-009584.

14.

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Wahlin A, Mailankody S, Blimark C, Hultcrantz M, Porwit A, Landgren O, Kristinsson SY.

Haematologica. 2016 Apr;101(4):e145-8. doi: 10.3324/haematol.2015.134049. Epub 2015 Dec 17. No abstract available.

15.

Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.

Weibull CE, Eloranta S, Smedby KE, Björkholm M, Kristinsson SY, Johansson AL, Dickman PW, Glimelius I.

J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14.

PMID:
26668344
16.

Brain tumors in patients with myotonic dystrophy: a population-based study.

Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Landgren O, Greene MH.

Eur J Neurol. 2016 Mar;23(3):542-7. doi: 10.1111/ene.12886. Epub 2015 Oct 28.

PMID:
26508558
17.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY.

JAMA Oncol. 2015 May;1(2):168-74. doi: 10.1001/jamaoncol.2015.23.

PMID:
26181017
18.

Survival in patients with familial and sporadic myeloproliferative neoplasms.

Hultcrantz M, Lund SH, Landgren O, Samuelsson J, Goldin LR, Oddsson A, Björkholm M, Kristinsson SY.

Blood. 2015 Jun 4;125(23):3665-6. doi: 10.1182/blood-2015-04-639039. No abstract available.

19.

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.

Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf ÅR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Björkholm M.

J Clin Oncol. 2015 Jul 10;33(20):2288-95. doi: 10.1200/JCO.2014.57.6652. Epub 2015 Jun 1.

PMID:
26033810
20.

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.

Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B.

Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213.

21.

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A.

Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.

22.

Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.

Steingrímsson V, Lund SH, Turesson I, Goldin LR, Björkholm M, Landgren O, Kristinsson SY.

Blood. 2015 Mar 26;125(13):2174-5. doi: 10.1182/blood-2015-01-622068. No abstract available.

23.

Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from Sweden.

Kristinsson SY, Gao Y, Björkholm M, Lund SH, Sjöberg J, Caporaso N, Goldin LR, Landgren O.

Int J Hematol. 2015 Jun;101(6):563-8. doi: 10.1007/s12185-015-1772-6. Epub 2015 Mar 11.

PMID:
25758095
24.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF.

Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.

PMID:
25439696
25.

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY.

Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.

26.

Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Hultcrantz M, Pfeiffer RM, Björkholm M, Goldin LR, Turesson I, Schulman S, Landgren O, Kristinsson SY.

J Thromb Haemost. 2014 Nov;12(11):1816-21. doi: 10.1111/jth.12724. Epub 2014 Oct 6.

27.

Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.

Hultcrantz M, Svensson T, Derolf ÅR, Kristinsson SY, Lindqvist EK, Ekbom A, Granath F, Björkholm M.

Cancer Med. 2015 Jan;4(1):147-54. doi: 10.1002/cam4.316. Epub 2014 Aug 26.

28.

The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms.

Oddsson A, Kristinsson SY, Helgason H, Gudbjartsson DF, Masson G, Sigurdsson A, Jonasdottir A, Jonasdottir A, Steingrimsdottir H, Vidarsson B, Reykdal S, Eyjolfsson GI, Olafsson I, Onundarson PT, Runarsson G, Sigurdardottir O, Kong A, Rafnar T, Sulem P, Thorsteinsdottir U, Stefansson K.

Leukemia. 2014 Jun;28(6):1371-4. doi: 10.1038/leu.2014.48. Epub 2014 Jan 30. No abstract available.

29.

Improved long-term survival in multiple myeloma up to the age of 80 years.

Kristinsson SY, Anderson WF, Landgren O.

Leukemia. 2014 Jun;28(6):1346-8. doi: 10.1038/leu.2014.23. Epub 2014 Jan 14. No abstract available.

PMID:
24418994
30.

Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis.

Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH.

PLoS One. 2013 Nov 13;8(11):e79851. doi: 10.1371/journal.pone.0079851. eCollection 2013.

31.

Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O.

Blood. 2014 Jan 16;123(3):338-45. doi: 10.1182/blood-2013-05-505487. Epub 2013 Nov 12.

32.

Treatment for high-risk smoldering myeloma.

Kristinsson SY, Holmberg E, Blimark C.

N Engl J Med. 2013 Oct 31;369(18):1762-3. doi: 10.1056/NEJMc1310911. No abstract available.

PMID:
24171527
33.

Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.

Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O.

Haematologica. 2014 Feb;99(2):392-8. doi: 10.3324/haematol.2013.092460. Epub 2013 Sep 20.

34.

No familial aggregation in chronic myeloid leukemia.

Björkholm M, Kristinsson SY, Landgren O, Goldin LR.

Blood. 2013 Jul 18;122(3):460-1. doi: 10.1182/blood-2013-05-501312. No abstract available.

35.

Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.

Kristinsson SY, Björkholm M, Landgren O.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):187-90. doi: 10.1016/j.clml.2013.02.010. Epub 2013 Mar 13. Review.

PMID:
23490991
36.

[Structuring and documenting research projects].

Eloranta S, Johansson AL, Kristinsson SY, Andersson TM.

Lakartidningen. 2013 Feb 20-26;110(8):416-9. Swedish. No abstract available.

PMID:
23488438
37.

Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Manasanch EE, Kristinsson SY, Landgren O.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):194-7. doi: 10.1016/j.clml.2013.02.002. Epub 2013 Mar 7. Review.

PMID:
23473950
38.

Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.

Kristinsson SY, Eloranta S, Dickman PW, Andersson TM, Turesson I, Landgren O, Björkholm M.

Am J Hematol. 2013 Jan;88(1):60-5. doi: 10.1002/ajh.23351. Epub 2012 Nov 19.

39.

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Björkholm M.

J Clin Oncol. 2012 Aug 20;30(24):2995-3001. doi: 10.1200/JCO.2012.42.1925. Epub 2012 Jul 16.

40.

Thrombosis is associated with inferior survival in multiple myeloma.

Kristinsson SY, Pfeiffer RM, Björkholm M, Schulman S, Landgren O.

Haematologica. 2012 Oct;97(10):1603-7. doi: 10.3324/haematol.2012.064444. Epub 2012 Apr 17.

41.

Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study.

Kristinsson SY, Goldin L, Turesson I, Hultcrantz M, Björkholm M, Landgren O.

J Thromb Haemost. 2012 May;10(5):962-4. doi: 10.1111/j.1538-7836.2012.04676.x. No abstract available.

42.

Thromboprophylaxis in multiple myeloma: is the evidence there?

Kristinsson SY, Landgren O.

Expert Rev Anticancer Ther. 2012 Mar;12(3):291-4. doi: 10.1586/era.11.214. No abstract available.

PMID:
22369320
43.

Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden.

Chang CM, Landgren O, Koshiol J, Björkholm M, Löve TJ, Kristinsson SY.

Int J Cancer. 2012 Nov 1;131(9):2208-9. doi: 10.1002/ijc.27483. Epub 2012 Mar 15. No abstract available.

44.

Second malignancies after multiple myeloma: from 1960s to 2010s.

Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O.

Blood. 2012 Mar 22;119(12):2731-7. doi: 10.1182/blood-2011-12-381426. Epub 2012 Feb 6. Review.

45.

Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Kristinsson SY, Goldin LR, Turesson I, Björkholm M, Landgren O.

Acta Haematol. 2012;127(3):173-7. doi: 10.1159/000335618. Epub 2012 Feb 3. Review.

46.

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.

Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.

Haematologica. 2012 Jun;97(6):854-8. doi: 10.3324/haematol.2011.054015. Epub 2011 Dec 16.

47.

Cancer risk among patients with myotonic muscular dystrophy.

Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH.

JAMA. 2011 Dec 14;306(22):2480-6. doi: 10.1001/jama.2011.1796.

48.

Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Goldin LR, Kristinsson SY, Liang XS, Derolf AR, Landgren O, Björkholm M.

J Clin Oncol. 2012 Jan 10;30(2):179-83. doi: 10.1200/JCO.2011.37.1203. Epub 2011 Dec 12.

49.

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009.

Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, Björkholm M.

Blood. 2012 Jan 26;119(4):990-6. doi: 10.1182/blood-2010-08-302604. Epub 2011 Dec 6.

50.

Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.

Lindqvist EK, Goldin LR, Landgren O, Blimark C, Mellqvist UH, Turesson I, Wahlin A, Björkholm M, Kristinsson SY.

Blood. 2011 Dec 8;118(24):6284-91. doi: 10.1182/blood-2011-04-347559. Epub 2011 Oct 13.

Supplemental Content

Loading ...
Support Center